Protagonist Therapeutics Cash Flow Statement
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Protagonist Therapeutics free cash flow
In fiscal 2025, Protagonist Therapeutics generated $57.7 million of operating cash flow and spent $1.6 million on capital expenditures. That left free cash flow of $56.1 million, a free-cash-flow margin of 121.9% of revenue. Free cash flow was down 69.3% from the prior year's $182.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Protagonist Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -130.15M | 275.19M | -78.95M | -127.39M | -125.55M | -66.15M | -77.19M | -38.92M | -36.96M | -37.18M |
| Net Income growth (YoY) | -147.29% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 1.28M | 826.00K | 977.00K | 1.03M | 813.00K | 948.00K | 732.00K | 527.00K | 406.00K | 317.00K |
| Stock-Based Compensation | 45.97M | 37.55M | 29.29M | 24.20M | 16.39M | 7.90M | 8.35M | 6.92M | 4.24M | 2.13M |
| Change in Working Capital | -19.65M | 27.64M | -1.11M | 4.20M | -17.61M | -27.73M | 27.49M | -17.98M | 31.51M | -1.92M |
| Operating Cash Flow | 57.67M | 184.15M | -70.24M | -108.14M | -107.86M | -72.48M | -41.53M | -49.95M | 3.87M | -29.97M |
| Capital Expenditures | -1.59M | -1.35M | -609.00K | -795.00K | -1.10M | -471.00K | -967.00K | -486.00K | -666.00K | -347.00K |
| Investing Cash Flow | -49.33M | -299.48M | -39.26M | 91.47M | -15.86M | -90.97M | -53.71M | 2.21M | 15.82M | -59.33M |
| Debt Issued | — | — | 24.30M | 14.55M | — | 42.06M | 9.77M | 1.51M | — | — |
| Debt Repaid | — | — | — | — | — | -10.52M | — | — | — | — |
| Financing Cash Flow | 22.86M | 25.85M | 170.48M | 18.84M | 129.92M | 247.63M | 46.04M | 24.11M | 65.55M | 106.31M |
| Net Change in Cash | 31.20M | -89.48M | 60.98M | 2.08M | 6.07M | 84.35M | -49.23M | -23.80M | 85.39M | 17.03M |
| Free Cash Flow | 56.08M | 182.80M | -70.84M | -108.93M | -108.97M | -72.95M | -42.49M | -50.43M | 3.21M | -30.32M |
This table shows 10 annual periods of Protagonist Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PTGX's reporting calendar. What is a cash flow statement?